Thermo Fisher Scientific EGFR Monoclonal Antibody (199.12)

Applications

Tested Dilution

Publications

Western Blot (WB)

2-4 µg/mL

View 10 publications 10 publications

Immunocytochemistry (ICC/IF)

5 µg/mL

View 13 publications 13 publications

Flow Cytometry (Flow)

-

View 4 publications 4 publications

ELISA (ELISA)

-

View 2 publications 2 publications

Immunoprecipitation (IP)

2 µg/mL

View 19 publications 19 publications

ChIP assay (ChIP)

-

View 1 publication 1 publication

Neutralization (Neu)

-

View 2 publications 2 publications

Blocking Assay (BLOCK)

-

View 1 publication 1 publication

Miscellaneous PubMed (Misc)

-

View 1 publication 1 publication

Product Specifications

Published species

Human, Mouse, Non-human primate, Rat

Host/Isotype

Mouse / IgG2a

Class

Monoclonal

Type

Antibody

Clone

199.12

Immunogen

Extracellular domain of human recombinant EGFR protein

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.2 mg/mL

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_10985841

Product Specific Information

MA5-13319 targets Epidermal Growth Factor Receptor in IP, ICC/IF and WB applications and shows reactivity with Human samples.

The MA5-13319 immunogen is extracellular domain of human recombinant EGFR protein.

Target Information

EGFR, epidermal growth factor receptor, is a receptor tyrosine kinases that signals in response to various growth factors. Overexpression has been linked to numerous types of cancer and EGFR is the target of both biological and small molecular therapeutics. EGFR is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.